RxDoctor Payments Data

Eric Straut

Optometrist · Melbourne, FLNPI 1194158337

Payments from drug & device makers

$585in general payments, 2019–2025

Across 22 payments — averaging $26.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$161
  • Glaukos Corporation$94
  • AbbVie$89
  • Novartis$45
  • Regeneron Healthcare Solutions, Inc.$44
  • Bausch & Lomb Americas Inc.$32
  • plus $119 from 5 others

What the payments were for

  • Food & beverage$585100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$585 in reported general payments places this provider in the 40th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$846,446
Medicare patients
2,552
Services billed
9,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine133$145,952
LumiganBimatoprost105$58,821
XiidraLifitegrast32$43,998
Cyclosporine63$38,858
RhopressaNetarsudil Mesylate40$19,753
Travoprost80$15,937
SimbrinzaBrinzolamide/Brimonidine Tart44$12,157
Latanoprost781$10,494
CombiganBrimonidine Tartrate/Timolol38$8,514
RocklatanNetarsudil Mesylat/Latanoprost12$5,672
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha506$5,449
Fluorometholone67$5,106
Brimonidine Tartrate207$4,530
Loteprednol Etabonate28$4,419
Prednisolone Acetate99$3,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$89$213,287276 claims
Bausch & Lomb Americas Inc.Xiidra$32$43,99832 claims
AlconSimbrinza$161$12,15744 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$20$4,41928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →